Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …

Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading
cause of cancer death in the United States. The authors provide contemporary lymphoid …

As the most common non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma
(DLBCL) incidence patterns generally parallel that for NHL overall. Globally, DLBCL …

Genome-wide association studies (GWAS) provide an agnostic approach for investigating
the genetic basis of complex diseases. In oncology, GWAS of nearly all common …

Diffuse large B-cell lymphoma (DLBCL), the most frequent subtype of lymphoid malignancy,
remains a significant clinical challenge, as∼ 30% of patients are not cured. Over the past …

Over 1.66 million humans (approx. 500/100 000 population rate) and over 4.2 million dogs
(approx. 5300/100 000 population rate) are diagnosed with cancer annually in the USA. The …

Our understanding of familial predisposition to lymphoma (collectively defined as non-
Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and chronic lymphocytic leukemia …

Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis.
Genome-wide association studies have transformed our understanding of MM …

Background: Studies of related individuals have consistently demonstrated notable familial
aggregation of cancer. We aim to estimate the heritability and genetic correlation attributable …